Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Losmapimod (Primary)
Indications Facioscapulohumeral muscular dystrophy
Focus Pharmacogenomic; Therapeutic Use
Acronyms ReDUX4
Sponsors Fulcrum Therapeutics

Most Recent Events

13 May 2024 According to a Fulcrum Therapeutics media release, results of this study were published in The Lancet Neurology.
08 May 2024 Results published in the Fulcrum Therapeutics Media Release.
08 May 2024 According to a Fulcrum Therapeutics media release, findings from this trial informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com